These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1913489)

  • 1. Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study.
    Ellis GK; Green S; Schulman S; Coltman CA; Hynes HE; Rivkin S; Livingston RB
    Cancer; 1991 Sep; 68(5):934-9. PubMed ID: 1913489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Neo-FAC' (5-fluorouracil, doxorubicin, and cyclophosphamide) for poor-prognosis stage IV breast cancer: a Southwest Oncology Group Phase II Study.
    Ellis GK; Green S; Livingston RB; Kraut MJ; Pierce HI; Paradelo JC; Taylor SA; Martino S
    Am J Clin Oncol; 1999 Oct; 22(5):446-9. PubMed ID: 10521055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study.
    Ellis GK; Green S; Schulman S; Tranum BL; Goldberg RS; Livingston RB
    Cancer; 1989 Dec; 64(12):2409-15. PubMed ID: 2684382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.
    Sparano JA; Wadler S; Liebes L; Robert NJ; Schwartz EL; Dutcher JP
    Cancer Res; 1993 Aug; 53(15):3509-12. PubMed ID: 8339255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
    Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
    Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.
    Loesch DM; Asmar L; Canfield VA; Parker GA; Hynes HE; Ellis PG; Ferri WA; Robert NJ
    Breast Cancer Res Treat; 2003 Jan; 77(2):115-23. PubMed ID: 12602910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of cyclophosphamide, doxorubicin, fluorouracil, and leucovorin for treatment of metastatic adenocarcinoma.
    Parnes HL; Abrams JS; Tait N; Minford J; Allen SL; Duggan D; Aisner J
    J Natl Cancer Inst; 1991 Jul; 83(14):1017-20. PubMed ID: 2072408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
    Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
    J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
    Moliterni A; Bonadonna G; Valagussa P; Ferrari L; Zambetti M
    J Clin Oncol; 1991 Jul; 9(7):1124-30. PubMed ID: 2045854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
    Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
    Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
    J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
    Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
    Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of dose-intensive continuous 5-fluorouracil, doxorubicin, and cyclophosphamide as adjuvant therapy for breast cancer.
    Ellis G; Livingston RB
    Cancer; 1993 Jan; 71(2):392-6. PubMed ID: 8422633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics. Cancer and Leukemia Group B.
    Kiang DT; Kennedy BJ; Younger J; Perry MC; Schilling A; Korzun AH; Nowak BS; Wood W
    Cancer; 1995 Feb; 75(3):826-30. PubMed ID: 7828133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer.
    Abeloff MD; Beveridge RA; Donehower RC; Fetting JH; Davidson NE; Gordon GG; Waterfield WC; Damron DJ
    J Natl Cancer Inst; 1990 Apr; 82(7):570-4. PubMed ID: 2313733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.